Combination therapy with PD-1 blockade and radiofrequency ablation for recurrent hepatocellular carcinoma: a propensity score matching analysis

Background This study aimed to evaluate whether combined therapy with PD-1 blockade (anti-PD-1) and radiofrequency ablation (RFA) is superior to RFA monotherapy for recurrent hepatocellular carcinoma (HCC). Methods A total of 127 patients who underwent anti-PD-1 plus RFA treatment (n = 41) or RFA al...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xiaofei Wang, Guo Liu, Shu Chen, Huaqiang Bi, Feng Xia, Kai Feng, Kuansheng Ma, Bing Ni
Formato:	article
Lenguaje:	EN
Publicado:	Taylor & Francis Group 2021
Materias:	hepatocellular carcinoma radiofrequency ablation pd-1 blockade t cell immune responses Medical technology R855-855.5
Acceso en línea:	https://doaj.org/article/ea4b83a7262447719d709a84064d968b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ea4b83a7262447719d709a84064d968b
record_format	dspace
spelling	oai:doaj.org-article:ea4b83a7262447719d709a84064d968b2021-11-04T15:00:41ZCombination therapy with PD-1 blockade and radiofrequency ablation for recurrent hepatocellular carcinoma: a propensity score matching analysis0265-67361464-515710.1080/02656736.2021.1991011https://doaj.org/article/ea4b83a7262447719d709a84064d968b2021-10-01T00:00:00Zhttp://dx.doi.org/10.1080/02656736.2021.1991011https://doaj.org/toc/0265-6736https://doaj.org/toc/1464-5157Background This study aimed to evaluate whether combined therapy with PD-1 blockade (anti-PD-1) and radiofrequency ablation (RFA) is superior to RFA monotherapy for recurrent hepatocellular carcinoma (HCC). Methods A total of 127 patients who underwent anti-PD-1 plus RFA treatment (n = 41) or RFA alone (n = 86) for recurrent HCC were included in this retrospective study. A matched cohort comprising 40 patients from each group was selected after propensity score matching analysis. Clinical data including post-RFA HCC recurrence (primary endpoint), overall survival (OS) (secondary endpoint), adverse events, and toxic effects were retrospectively analyzed. Results The 1-year recurrence-free survival rates for the anti-PD-1 plus RFA and RFA groups were 32.5% and 10.0% after propensity score matching. There were statistically significant differences between the two groups in terms of the recurrence-free survival rate (p = 0.001) and OS rate (p = 0.016). Tumor number, tumor-node metastasis (TNM) stage, antiviral therapy, and anti-PD-1 treatment were demonstrated to be important factors associated with 1-year recurrence-free survival probability by univariate and multivariate analyses. Univariate and multivariate analyses demonstrated that tumor number, TNM stage and anti-PD-1 treatment were significant prognostic factors for OS. RFA treatment-related adverse events included pleural effusions that require drainage and a mild or moderate increase in body temperature. Grade 3 or higher events related to anti-PD-1 treatment occurred in 12.8% (6) of patients and were infrequent. Conclusions Combination therapy with anti-PD-1 plus RFA was superior to RFA alone in improving survival in patients with recurrent HCC.Xiaofei WangGuo LiuShu ChenHuaqiang BiFeng XiaKai FengKuansheng MaBing NiTaylor & Francis Grouparticlehepatocellular carcinomaradiofrequency ablationpd-1 blockadet cellimmune responsesMedical technologyR855-855.5ENInternational Journal of Hyperthermia, Vol 38, Iss 1, Pp 1519-1528 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	hepatocellular carcinoma radiofrequency ablation pd-1 blockade t cell immune responses Medical technology R855-855.5
spellingShingle	hepatocellular carcinoma radiofrequency ablation pd-1 blockade t cell immune responses Medical technology R855-855.5 Xiaofei Wang Guo Liu Shu Chen Huaqiang Bi Feng Xia Kai Feng Kuansheng Ma Bing Ni Combination therapy with PD-1 blockade and radiofrequency ablation for recurrent hepatocellular carcinoma: a propensity score matching analysis
description	Background This study aimed to evaluate whether combined therapy with PD-1 blockade (anti-PD-1) and radiofrequency ablation (RFA) is superior to RFA monotherapy for recurrent hepatocellular carcinoma (HCC). Methods A total of 127 patients who underwent anti-PD-1 plus RFA treatment (n = 41) or RFA alone (n = 86) for recurrent HCC were included in this retrospective study. A matched cohort comprising 40 patients from each group was selected after propensity score matching analysis. Clinical data including post-RFA HCC recurrence (primary endpoint), overall survival (OS) (secondary endpoint), adverse events, and toxic effects were retrospectively analyzed. Results The 1-year recurrence-free survival rates for the anti-PD-1 plus RFA and RFA groups were 32.5% and 10.0% after propensity score matching. There were statistically significant differences between the two groups in terms of the recurrence-free survival rate (p = 0.001) and OS rate (p = 0.016). Tumor number, tumor-node metastasis (TNM) stage, antiviral therapy, and anti-PD-1 treatment were demonstrated to be important factors associated with 1-year recurrence-free survival probability by univariate and multivariate analyses. Univariate and multivariate analyses demonstrated that tumor number, TNM stage and anti-PD-1 treatment were significant prognostic factors for OS. RFA treatment-related adverse events included pleural effusions that require drainage and a mild or moderate increase in body temperature. Grade 3 or higher events related to anti-PD-1 treatment occurred in 12.8% (6) of patients and were infrequent. Conclusions Combination therapy with anti-PD-1 plus RFA was superior to RFA alone in improving survival in patients with recurrent HCC.
format	article
author	Xiaofei Wang Guo Liu Shu Chen Huaqiang Bi Feng Xia Kai Feng Kuansheng Ma Bing Ni
author_facet	Xiaofei Wang Guo Liu Shu Chen Huaqiang Bi Feng Xia Kai Feng Kuansheng Ma Bing Ni
author_sort	Xiaofei Wang
title	Combination therapy with PD-1 blockade and radiofrequency ablation for recurrent hepatocellular carcinoma: a propensity score matching analysis
title_short	Combination therapy with PD-1 blockade and radiofrequency ablation for recurrent hepatocellular carcinoma: a propensity score matching analysis
title_full	Combination therapy with PD-1 blockade and radiofrequency ablation for recurrent hepatocellular carcinoma: a propensity score matching analysis
title_fullStr	Combination therapy with PD-1 blockade and radiofrequency ablation for recurrent hepatocellular carcinoma: a propensity score matching analysis
title_full_unstemmed	Combination therapy with PD-1 blockade and radiofrequency ablation for recurrent hepatocellular carcinoma: a propensity score matching analysis
title_sort	combination therapy with pd-1 blockade and radiofrequency ablation for recurrent hepatocellular carcinoma: a propensity score matching analysis
publisher	Taylor & Francis Group
publishDate	2021
url	https://doaj.org/article/ea4b83a7262447719d709a84064d968b
work_keys_str_mv	AT xiaofeiwang combinationtherapywithpd1blockadeandradiofrequencyablationforrecurrenthepatocellularcarcinomaapropensityscorematchinganalysis AT guoliu combinationtherapywithpd1blockadeandradiofrequencyablationforrecurrenthepatocellularcarcinomaapropensityscorematchinganalysis AT shuchen combinationtherapywithpd1blockadeandradiofrequencyablationforrecurrenthepatocellularcarcinomaapropensityscorematchinganalysis AT huaqiangbi combinationtherapywithpd1blockadeandradiofrequencyablationforrecurrenthepatocellularcarcinomaapropensityscorematchinganalysis AT fengxia combinationtherapywithpd1blockadeandradiofrequencyablationforrecurrenthepatocellularcarcinomaapropensityscorematchinganalysis AT kaifeng combinationtherapywithpd1blockadeandradiofrequencyablationforrecurrenthepatocellularcarcinomaapropensityscorematchinganalysis AT kuanshengma combinationtherapywithpd1blockadeandradiofrequencyablationforrecurrenthepatocellularcarcinomaapropensityscorematchinganalysis AT bingni combinationtherapywithpd1blockadeandradiofrequencyablationforrecurrenthepatocellularcarcinomaapropensityscorematchinganalysis
_version_	1718444807126253568

Combination therapy with PD-1 blockade and radiofrequency ablation for recurrent hepatocellular carcinoma: a propensity score matching analysis

Ejemplares similares